Newborn Cardiac SurgeryhemostasisNCT06166940
Comparison Of The Two Types Of Hemostasis Management Effectiveness : Thromboelastometry (Rotem) Guided Management And Conventional Method In Newborn Congenital Cardiac Surgery Patients
An observational study of Newborn Cardiac Surgery and Newborn Hemostasis, run by Başakşehir Çam & Sakura City Hospital at 1 site in Turkey (Türkiye).
Trial summary
Sixty consecutive newborn patients who underwent pediatric cardiac surgery from April 2022 to October 2023 at Basaksehir Cam and Sakura City Hospital) were included in this study. Data of eighty-six patients who received ROTEM guided transfusions after August 15, 2022 was collected. Read more about this study
- Who is it for?
- Ages 0 to 30 days
- Conditions the study is for
- Newborn Cardiac Surgery, Newborn Hemostasis
- What is being tested?
- ROTEM Guided Management
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Mar 2022to 1 Oct 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 30 days
- All sexes
- No healthy volunteers
- Child
Study population: Newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass
Who may be able to join
- newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass
Who cannot join
- the newborn patients who did not need cardiopulmonary bypass during surgery were excluded.
- the newborns whose records are missing were excluded
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Basaksehir Cam and Sakura City Hospital
Istanbul
About this study
Sixty consecutive newborn patients who underwent pediatric cardiac surgery from April 2022 to October 2023 at Basaksehir Cam and Sakura City Hospital) were included in this study. Data of eighty-six patients who received ROTEM guided transfusions after August 15, 2022 was collected. First sixteen patients were given cryoprecipitate in the middle of the Modified ultra-filtration (MUF) procedure according to previous conventional approach, and so these patients excluded. And ten patients were excluded due to the lack of information. Thirty patients, who received ROTEM guided transfusions compared to the prior thirty patients who received transfusions conventionally. There was no randomization and standardized anesthesia and surgical techniques were used.
Anesthesia induction conducted with midazolam, ketamine, fentanyl, and rocuronium bromide; and antifibrinolytic (tranexamic acid) infusion was used during operation till the closure of skin. Anesthesia and cardiopulmonary bypass(CPB) anesthesia was maintained with remifentanil, midazolam, ketamine and rocuronium, and sevoflurane -not during bypass. Size-adapted bypass circuits and membrane oxygenators (FX05 oxygenators) were used. Total priming volume for the bypass circuit was 250 - 400 ml, consisting of red blood cell (RBC), fresh frozen plasma (FFP), Isolyte-S solution, mannitol, sodium bicarbonate, tranexamic acid, prednisol, and antibiotic. Anticoagulation during CPB was managed with 350 U/kg unfractioned heparin (Novo-Heparin) and additional boluses of 50 U/kg, as needed, to maintain an activated clotting time (ACT) of at least 450s. Heparin anticoagulation was antagonized with 3,5 mg/kg protamine.
Read more
Red blood cell concentrates were transfused to maintain the haematocrit at 28 - 32% during cardiopulmonary bypass (CPB). Bypass was conducted under mild (core temperature 32°C ) and moderate (core temperature 28 °C) hypothermia. Myocardial protection was achieved with cold intermittent blood cardioplegia (20 ml/kg), which was prepared during CPB by adding buffered del nido solution (Plasma-Lyte A) in the ratio 1:4 to whole blood obtained from the arterial line. The cardioplegia solution was kept at 6°C before infusion. Blood sample for running ROTEM analysis were taken just before weaning CPB, when the core temperature of patients were 36-37 °C. MUF was performed after weaning from CPB and 5-10 minutes before protamine administration, with a target haematocrit of 35-40%. After heparin antagonization, RBC transfusions applied with a target haematocrit of 35-40 % for non-cyanotic patients, and 40-45% for cyanotic patients.
We collected data on the following subject characteristics: height (cm); weight (kg); age (days); gender; presence of cyanosis; presence of ay genetic disorder; Aristotle score (1,5-25); duration of the surgical procedure (min); CPB time (min); aortic cross clamp time (min); the lowest core temperature during CPB; total amount of blood products transfused after CPB intraoperatively (ml/kg), including red blood cell concentrates, FFP, platelet concentrates, cryoprecipitate, and fibrinogen concentrates; total amount of blood products transfused after operation up to 24 h after admission to the Pediatric Cardiac Intensive Care Unit (PCICU) (ml/kg); total amount of chest tube drainage after operation up to 24 h after PCICU admission (ml/kg); 28 day survival; extracorporeal membrane oxygenator (ECMO) application; and need for peritoneal dialysis.
In all patients, routine blood samples for hemoglobin (Hb), haematocrit (Hct), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count; renal function tests urea and creatinine were collected preoperatively. Hb, Hct, PT, INR, aPTT, platelet count, urea and creatinine were also analyzed on the first postoperative morning.
We conducted thromboelastometry in the operating theatre (OR) using the ROTEM device. Four assays-EXTEM, INTEM, FIBTEM, and HEPTEM were tested in citrated whole blood. Because the patients were still under heparin effect when the samples were taken, we made transfusion adjustments according to EXTEM and FIBTEM test results. Since we got the EXTEM, FIBTEM A5 results as soon as heparin antagonization was complete, we transfused the blood products according to the results. We also collected those data.
The primary outcome was the proportion of perioperative transfusion (intraoperatively and in the PCICU) in the ROTEM group and in the conventional group. The secondary outcomes are postoperative chest tube drainage up to 24 hours; need for peritoneal dialysis. The other analyses have mainly a descriptive purpose.
Read the detailed description
Four main scenarios based on clinical observation and ROTEM results were possible:
- Insignificant bleeding-normal ROTEM; no transfusions
- Insignificant bleeding-abnormal ROTEM; no transfusions
- Significant bleeding-normal ROTEM; surgical reevaluation
- Significant bleeding-abnormal ROTEM; transfusion of blood products as indicated by:
- FIBTEM A5 <9 mm -fibrinogen concentrate or cryoprecipitate
- 9mm ≤ FIBTEM A5 <13mm and or EXTEM CT > 80 seconds fibrinogen concentrate or cryoprecipitate and significant bleeding still continued with EXTEM A5 < 35 mm - platelet concentrate
- FIBTEM A5 >13mm and EXTEM A5 < 35 mm -platelet concentrate
- After transfusions if the bleeding was still continuing, while surgical reevaluation was in progress, we gave fibrinogen concentrate to replace the lost fibrinogen with the ongoing bleeding. At the same time to verify the treatment effect and control heparin reversal, a second set of INTEM, HEPTEM, EXTEM and FIBTEM analyses were also performed during wound closure. ACT was tested in all patients to control for heparin reversal. If patients had both a pathological ACT and ROTEM (CTIN/ CTHEP ratio ≥ 1,25) protamine was administered first. After fibrinogen and platelet transfusions, if INTEM CT > 280 seconds and HEPTEM CT > 280 seconds with continuing bleeding FFP were given.
Blood transfusion after paediatric intensive care unit (PCICU) admission was managed without ROTEM guidance by paediatric cardiac surgeons and intensivists.
- Conditions
- Newborn Cardiac Surgery, Newborn Hemostasis
- Being tested
- ROTEM Guided Management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ROTEM Guided ManagementOther
ROTEM guided management of hemostasis after CPB
| Study group | Role | What they receive |
|---|---|---|
| Conventional Management | Not described Receives: Other: ROTEM Guided Management |
What is being measured
The primary outcome is the main question the study is designed to answer.
perioperative transfusion
the proportion of perioperative transfusion of RBC, fibrinogen concentrate, platelet concentrate, FFP in milliliters
Measured: after weaning from cardiopulmonary bypass up to the end 24 hours
Secondary outcomes (1)
postoperative bleeding
postoperative chest tube drainage in milliliters
Measured: from the admission of the pediatric cardiac intensive care unit up to 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2023
- Study start1 Mar 2022
- Primary completion1 Oct 2023
- Study completion1 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Newborn Cardiac SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Başakşehir Çam & Sakura City Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06166940
- Sponsor's protocol ID
- 2023.11.11
- Acronym
- hemostasis
- Status last verified
- Mar 2022
- First submitted
- 4 Dec 2023
- Last updated
- 12 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Of The Two Types Of Hemostasis Management Effectiveness : Thromboelastometry (Rotem) Guided Management And Conventional Method In Newborn Congenital Cardiac Surgery Patients
- ClinicalTrials.gov ID
- NCT06166940
- Acronym / sponsor ID
- hemostasis / 2023.11.11
- Conditions
- Newborn Cardiac Surgery, Newborn Hemostasis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Başakşehir Çam & Sakura City HospitalOther government
- Study start
- 1 Mar 2022 (actual)
- Primary completion
- 1 Oct 2023 (actual)
- Study completion
- 1 Oct 2023 (actual)
- First posted
- 12 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sixty consecutive newborn patients who underwent pediatric cardiac surgery from April 2022 to October 2023 at Basaksehir Cam and Sakura City Hospital) were included in this study. Data of eighty-six patients who received ROTEM guided transfusions after August 15, 2022 was collected. First sixteen patients were given cryoprecipitate in the middle of the Modified ultra-filtration (MUF) procedure according to previous conventional approach, and so these patients excluded. And ten patients were excluded due to the lack of information. Thirty patients, who received ROTEM guided transfusions compared to the prior thirty patients who received transfusions conventionally. There was no randomization and standardized anesthesia and surgical techniques were used.
Anesthesia induction conducted with midazolam, ketamine, fentanyl, and rocuronium bromide; and antifibrinolytic (tranexamic acid) infusion was used during operation till the closure of skin. Anesthesia and cardiopulmonary bypass(CPB) anesthesia was maintained with remifentanil, midazolam, ketamine and rocuronium, and sevoflurane -not during bypass. Size-adapted bypass circuits and membrane oxygenators (FX05 oxygenators) were used. Total priming volume for the bypass circuit was 250 - 400 ml, consisting of red blood cell (RBC), fresh frozen plasma (FFP), Isolyte-S solution, mannitol, sodium bicarbonate, tranexamic acid, prednisol, and antibiotic. Anticoagulation during CPB was managed with 350 U/kg unfractioned heparin (Novo-Heparin) and additional boluses of 50 U/kg, as needed, to maintain an activated clotting time (ACT) of at least 450s. Heparin anticoagulation was antagonized with 3,5 mg/kg protamine.
Red blood cell concentrates were transfused to maintain the haematocrit at 28 - 32% during cardiopulmonary bypass (CPB). Bypass was conducted under mild (core temperature 32°C ) and moderate (core temperature 28 °C) hypothermia. Myocardial protection was achieved with cold intermittent blood cardioplegia (20 ml/kg), which was prepared during CPB by adding buffered del nido solution (Plasma-Lyte A) in the ratio 1:4 to whole blood obtained from the arterial line. The cardioplegia solution was kept at 6°C before infusion. Blood sample for running ROTEM analysis were taken just before weaning CPB, when the core temperature of patients were 36-37 °C. MUF was performed after weaning from CPB and 5-10 minutes before protamine administration, with a target haematocrit of 35-40%. After heparin antagonization, RBC transfusions applied with a target haematocrit of 35-40 % for non-cyanotic patients, and 40-45% for cyanotic patients.
We collected data on the following subject characteristics: height (cm); weight (kg); age (days); gender; presence of cyanosis; presence of ay genetic disorder; Aristotle score (1,5-25); duration of the surgical procedure (min); CPB time (min); aortic cross clamp time (min); the lowest core temperature during CPB; total amount of blood products transfused after CPB intraoperatively (ml/kg), including red blood cell concentrates, FFP, platelet concentrates, cryoprecipitate, and fibrinogen concentrates; total amount of blood products transfused after operation up to 24 h after admission to the Pediatric Cardiac Intensive Care Unit (PCICU) (ml/kg); total amount of chest tube drainage after operation up to 24 h after PCICU admission (ml/kg); 28 day survival; extracorporeal membrane oxygenator (ECMO) application; and need for peritoneal dialysis.
In all patients, routine blood samples for hemoglobin (Hb), haematocrit (Hct), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count; renal function tests urea and creatinine were collected preoperatively. Hb, Hct, PT, INR, aPTT, platelet count, urea and creatinine were also analyzed on the first postoperative morning.
We conducted thromboelastometry in the operating theatre (OR) using the ROTEM device. Four assays-EXTEM, INTEM, FIBTEM, and HEPTEM were tested in citrated whole blood. Because the patients were still under heparin effect when the samples were taken, we made transfusion adjustments according to EXTEM and FIBTEM test results. Since we got the EXTEM, FIBTEM A5 results as soon as heparin antagonization was complete, we transfused the blood products according to the results. We also collected those data.
The primary outcome was the proportion of perioperative transfusion (intraoperatively and in the PCICU) in the ROTEM group and in the conventional group. The secondary outcomes are postoperative chest tube drainage up to 24 hours; need for peritoneal dialysis. The other analyses have mainly a descriptive purpose.
Detailed description
Four main scenarios based on clinical observation and ROTEM results were possible:
- Insignificant bleeding-normal ROTEM; no transfusions
- Insignificant bleeding-abnormal ROTEM; no transfusions
- Significant bleeding-normal ROTEM; surgical reevaluation
- Significant bleeding-abnormal ROTEM; transfusion of blood products as indicated by:
- FIBTEM A5 <9 mm -fibrinogen concentrate or cryoprecipitate
- 9mm ≤ FIBTEM A5 <13mm and or EXTEM CT > 80 seconds fibrinogen concentrate or cryoprecipitate and significant bleeding still continued with EXTEM A5 < 35 mm - platelet concentrate
- FIBTEM A5 >13mm and EXTEM A5 < 35 mm -platelet concentrate
- After transfusions if the bleeding was still continuing, while surgical reevaluation was in progress, we gave fibrinogen concentrate to replace the lost fibrinogen with the ongoing bleeding. At the same time to verify the treatment effect and control heparin reversal, a second set of INTEM, HEPTEM, EXTEM and FIBTEM analyses were also performed during wound closure. ACT was tested in all patients to control for heparin reversal. If patients had both a pathological ACT and ROTEM (CTIN/ CTHEP ratio ≥ 1,25) protamine was administered first. After fibrinogen and platelet transfusions, if INTEM CT > 280 seconds and HEPTEM CT > 280 seconds with continuing bleeding FFP were given.
Blood transfusion after paediatric intensive care unit (PCICU) admission was managed without ROTEM guidance by paediatric cardiac surgeons and intensivists.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Conventional Management | – | Other: ROTEM Guided Management |
Who may qualify
- Ages
- 0 to 30 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass
Key inclusion criteria (1 listed)
- newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass
Key exclusion criteria (2 listed)
- the newborn patients who did not need cardiopulmonary bypass during surgery were excluded.
- the newborns whose records are missing were excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ROTEM Guided ManagementROTEM guided management of hemostasis after CPB | Other | Conventional Management |
Primary outcome
perioperative transfusion
Time frame: after weaning from cardiopulmonary bypass up to the end 24 hours
the proportion of perioperative transfusion of RBC, fibrinogen concentrate, platelet concentrate, FFP in milliliters
1 secondary outcome
postoperative bleeding
Time frame: from the admission of the pediatric cardiac intensive care unit up to 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2023.
Related trials for Newborn Cardiac Surgery
RecruitingPhase 1/2
Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
Congenital Heart Disease (CHD)
Not yet recruiting
Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery
Congenital Heart Disease (CHD), Postoperative Sleep
Active, not recruiting
Autus Valve Continued Access Study (CAS)
Congenital Heart Disease
Active, not recruiting
Autus Valve Pivotal Study
Congenital Heart Disease
RecruitingPhase 3
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
Hypoplastic Left Heart Syndrome, Single Ventricle
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Newborn Cardiac Surgery and Newborn Hemostasis, run by Başakşehir Çam & Sakura City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
perioperative transfusion (time frame: after weaning from cardiopulmonary bypass up to the end 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2023.